Get the Stockscreener App
0.0457
70.31%
-0.1082
After Hours:
.05
0.0043
+9.41%
Carisma Therapeutics Inc stock is traded at $0.0457, with a volume of 5.07M.
It is down -70.31% in the last 24 hours and down -87.78% over the past month.
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.
See More
Previous Close:
$0.1539
Open:
$0.086
24h Volume:
5.07M
Relative Volume:
0.66
Market Cap:
$1.91M
Revenue:
$20.27M
Net Income/Loss:
$-63.80M
P/E Ratio:
-0.0301
EPS:
-1.52
Net Cash Flow:
$-68.35M
1W Performance:
-82.15%
1M Performance:
-87.78%
6M Performance:
-77.92%
1Y Performance:
-95.09%
1-Day Range:
$0.0452
$0.0999
1-Week Range:
$0.0452
$0.29
52-Week Range:
$0.0452
$1.27
Carisma Therapeutics Inc Stock (CARM) Company Profile
Name
Carisma Therapeutics Inc
Sector
Industry
Phone
(267) 491-6422
Address
3675 MARKET STREET, PHILADELPHIA
Compare CARM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CARM
Carisma Therapeutics Inc
|
0.0457 | 6.43M | 20.27M | -63.80M | -68.35M | -1.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Carisma Therapeutics Inc Stock (CARM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-10-24 | Downgrade | BTIG Research | Buy → Neutral |
| Apr-11-24 | Initiated | BTIG Research | Buy |
| Oct-03-23 | Initiated | CapitalOne | Overweight |
| Jul-06-23 | Initiated | Evercore ISI | Outperform |
| May-31-23 | Upgrade | Jefferies | Hold → Buy |
| May-24-23 | Initiated | H.C. Wainwright | Buy |
| Apr-14-23 | Initiated | Robert W. Baird | Outperform |
View All
Carisma Therapeutics Inc Stock (CARM) Latest News
Visual trend scoring systems applied to Carisma Therapeutics Inc.Quarterly Trade Review & Free Community Supported Trade Ideas - newser.com
Heatmap analysis for Carisma Therapeutics Inc. and competitorsEarnings Recap Summary & Fast Entry High Yield Stock Tips - newser.com
How hedge fund analytics apply to Carisma Therapeutics Inc. stockJuly 2025 Snapshot & Weekly Watchlist for Hot Stocks - newser.com
What analyst consensus says on Carisma Therapeutics Inc. stockGap Down & Weekly Top Performers Watchlists - newser.com
Will Carisma Therapeutics Inc. stock go up soonDollar Strength & Fast Entry High Yield Stock Tips - newser.com
What MACD trends signal for Carisma Therapeutics Inc. (W2J) stock2025 Fundamental Recap & Weekly High Return Forecasts - newser.com
Using Bollinger Bands to evaluate Carisma Therapeutics Inc.Market Risk Summary & Risk Managed Investment Strategies - newser.com
Analyzing recovery setups for Carisma Therapeutics Inc. investorsWeekly Gains Report & Free Daily Entry Point Trade Alerts - newser.com
Dow Surges 150 Points; US Consumer Sentiment Edges Lower - Benzinga
Carisma Therapeutics stock plunges after Nasdaq delisting notice By Investing.com - Investing.com Canada
Carisma Therapeutics stock plunges after Nasdaq delisting notice - Investing.com
Can Carisma Therapeutics Inc. (W2J) stock sustain free cash flowJuly 2025 Levels & Weekly High Conviction Ideas - newser.com
Carisma Therapeutics Faces Nasdaq Delisting and Trading Suspension - TipRanks
Key metrics from Carisma Therapeutics Inc.’s quarterly dataDividend Hike & Smart Money Movement Alerts - newser.com
Top Executive Sells Thousands of Carisma Therapeutics Shares! - TipRanks
Carisma Therapeutics CSO Sells Shares - TradingView
Is Carisma Therapeutics Inc a good long term investmentTechnology Stock Trends & Free Trend Following Techniques - earlytimes.in
Is Carisma Therapeutics Inc W2J a good long term investmentVolume Weighted Average Price & Low Entry Investment Portfolio - earlytimes.in
Chart overlay techniques for tracking Carisma Therapeutics Inc.Earnings Miss & Low Drawdown Momentum Trade Ideas - newser.com
Can machine learning forecast Carisma Therapeutics Inc. recoveryJuly 2025 Opening Moves & Consistent Profit Trade Alerts - newser.com
Is Carisma Therapeutics Inc. a candidate for recovery playMarket Growth Summary & Real-Time Volume Trigger Notifications - newser.com
Advanced analytics toolkit walkthrough for Carisma Therapeutics Inc.Weekly Trade Analysis & High Accuracy Swing Entry Alerts - newser.com
Is Carisma Therapeutics Inc. stock attractive for passive investorsPortfolio Risk Summary & AI Powered Market Trend Analysis - newser.com
How analysts revise price targets for Carisma Therapeutics Inc. (W2J) stockInsider Selling & AI Enhanced Trading Alerts - newser.com
Why Carisma Therapeutics Inc. (W2J) stock is listed among top recommendationsEarnings Risk Report & Fast Gain Stock Tips - newser.com
Should you wait for a breakout in Carisma Therapeutics Inc.2025 Support & Resistance & Daily Oversold Bounce Ideas - newser.com
P 500 performance this yearJuly 2025 PostEarnings & High Yield Stock Recommendations - newser.com
What analysts say about Carisma Therapeutics Inc stockMarket Profile Overview & Small Investment Portfolio - earlytimes.in
Carisma Therapeutics Inc Stock (CARM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):